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Summary 
Medications used to control hypertension in pregnancy also improve trophoblast 
and endothelial cellular interaction in vitro. Tumour necrosis factor-α (TNF-α) 
inhibits trophoblast and endothelial cellular interactions and simultaneously 
decreases endothelial nitric oxide synthase (eNOS) expression.  This study 
investigated whether antihypertensive medications improved these cellular 
interactions by modulating eNOS and inducible nitric oxide synthase (iNOS) 
expression. Human uterine myometrial microvascular endothelial cells (UtMVECs) 
were pre-incubated with (or without) low dose TNF-α (0.5 ng/ml) or TNF-α plus 
soluble fms-like tyrosine kinase-1 (sFlt-1) (100 ng/ml). The endothelial cells were 
cultured on Matrigel. After endothelial cellular networks appeared, trophoblast 
derived HTR-8/SVneo cells were co-cultured in the presence of clinically relevant 
doses of methyldopa, labetalol, hydralazine or clonidine for 24 hours. Cells were 










This article is protected by copyright. All rights reserved. 
examined by quantitative PCR. Methyldopa, labetalol, hydralazine and clonidine 
reversed the inhibitory effect of TNF-α on eNOS mRNA expression. After pre-
incubating endothelial cells with TNF-α and sFlt-1, all the medications except 
methyldopa lost their effect on eNOS mRNA expression. In the absence of TNF-α, 
antihypertensive medications did not change eNOS expression. The mRNA 
expression of iNOS was not affected by TNF-α or any medications. This study 
shows that selected antihypertensive medications used in the treatment of 
hypertension in pregnancy increase eNOS expression in vitro when induced by the 
inflammatory TNF-α. The antiangiogenic molecule sFlt-1 may antagonise the 
potential benefit of these medications by interfering with the NOS pathway. 
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Introduction 
In pregnancy, the uteroplacental vasculature undergoes a profound change where a 
marked increase in uteroplacental blood flow is achieved by a reduction in vascular 
resistance. Trophoblasts invade into the uterine spiral arteries transforming them 
into low resistance vessels [1] [2].  Failure of spiral artery transformation and poor 
placental invasion of the uterine vasculature by trophoblast cells [3] are implicated 
in the pathogenesis of preeclampsia, a significant and common complication of 
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Nitric oxide (NO) is a potent vasorelaxant that contributes to the reduction in 
peripheral vascular resistance during pregnancy [6] [7] [8]. There are three isoforms 
of nitric oxide synthase (NOS) which produce NO. Neuronal NOS (nNOS) and 
endothelial NOS (eNOS) are constitutively expressed and are dependent on Ca2+ 
and calmodulin to produce small basal levels of NO for vasodilatation and 
maintenance of vascular tone [9]. In contrast, Ca2+ independent inducible NOS 
(iNOS) is stimulated by proinflammatory molecules to liberate a great amount of NO 
and cause cell damage [10]. During gestation, eNOS and iNOS are expressed and 
dynamically regulated in the trophoblast and endothelial cells of the placenta [11] 
[12] [13]. iNOS has been shown to play a role in promoting trophoblast invasion 
[14]. 
 
We have previously established an in vitro model of trophoblast invasion, where we 
have shown that the proinflammatory molecule TNF-α, found in higher levels in the 
sera of preeclamptic women [15] inhibits the integration of trophoblast cells into 
endothelial cell networks, and simultaneously decreases eNOS expression [16] [17]. 
The NO donor, sodium nitroprusside dehydrate, reversed the inhibitory effects of 
TNF-α on integration and eNOS expression [17]. More recently we have shown that 
antihypertensive medications administered selectively to control hypertension in 
pregnancy, such as methyldopa, labetalol, hydralazine and clonidine, can improve 
trophoblast interaction with endothelial cellular networks. These medications are the 
most commonly used for everyday treatment of hypertension in pregnancy [18]. 
However, whether these antihypertensive medications modulate the interaction 
between trophoblast and endothelial cells via the NOS pathway is yet to be 
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agonist, induces vascular relaxation by a nitric oxide-dependent mechanism [19] 
and enhances iNOS mRNA expression [20]. The vasodilator hydralazine has been 
reported to reduce NO production and iNOS gene expression in macrophages [21] 
but to have no effect on any NOS protein expression in the brain [[22]. There are no 
reported studies on the effect of the indirectly acting α2-adrenergic agonist 
methyldopa or of labetalol, the combined α-1/β adrenergic antagonist, on NOS 
activity or expression.  
 
The aim of this study is to investigate whether the antihypertensive medications 
typically used during pregnancy; methyldopa, labetalol, hydralazine and clonidine, 
alter the interaction between human trophoblast and endothelial cells via modulation 
of eNOS and iNOS expression. Further, we aim to investigate whether the presence 
of the antiangiogenic molecule soluble fms-like tyrosine kinase-1 (sFlt-1), which is 
found in elevated levels in preeclamptic women and thought to be involved in its 
pathogenesis [23] attenuates the eNOS and iNOS response. 
 
Results 
Concurrent administration of anti-hypertensives reverses the TNF-α induced 
reduction of eNOS expression in co-cultured cells 
The addition of the proinflammatory cytokine TNF-α to the co-cultured endothelial 
and trophoblast cells resulted in a decrease of the eNOS mRNA expression to 
35±6% of control co-cultured cells (Figure 1, **p<0.01). Concurrent addition 
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the inhibitory effect of TNF-α on eNOS expression (Figure 1, ***p<0.001), but also 
increased eNOS expression to that of 109±15% (methyldopa) 144±26% (labetalol), 
286±73% (hydralazine) and 210±48% (clonidine) of control co-cultures. In the 
absence of TNF-α, none of the medications had an effect on eNOS expression 
(Figure 1). In the absence of endothelial cells, trophoblast HTR-8 cells alone 
cultured on matrigel did not express eNOS (see supplemental data). 
 
Anti-hypertensives prevent reduced eNOS expression in co-cultured cells 
after endothelial cell pre-exposure to TNF-α  
In order to simulate a situation when the inflammatory pathway has already been 
activated prior to addition of the anti-hypertensives, endothelial cells were pre-
exposed to TNF-α prior to co-culture. Preincubating UtMVECs with TNF-α before 
endothelial cellular networks formed also resulted in an inhibition of eNOS mRNA 
expression. This was noted with co-cultured cells (Figure 2, 51±19% of control cells, 
*p<0.05), and with the addition of the selected medications methyldopa, labetalol, 
hydralazine and clonidine. Under these conditions a significant augmentation of 
eNOS mRNA expression compared to control cells was only observed with labetalol 
(170±26%), hydralazine (192±43%) and clonidine (146±15%) but not methyldopa 
(87±15%) (Figure 2, *p<0.05, **p<0.01, ***p<0.001 respectively). A comparison of 
the effects of medications on eNOS expression when endothelial cells were pre-
incubated with TNF-α or when TNF-α was added concurrently with medications was 
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The anti-angiogenic molecule sFLT-1 modulates the eNOS response to TNF-α 
and anti-hypertensives 
As the anti-angiogenic molecule sFLt-1 was also found to be elevated in the plasma 
of women with preeclampsia, we assessed the eNOS response of the co-culture 
system when the endothelial cells were pre-incubated with both TNF-α and sFlt-1. 
The inhibition of eNOS expression observed with TNF-α alone was negated.  
Labetalol (87±13%), hydralazine (101±16%) and clonidine(121±20%), except 
methyldopa (129±18%, *p<0.05) diminished their effects on eNOS expression 
(Figure 3).  
 
TNF-α or anti-hypertensives have no effect on iNOS expression 
The mRNA expression of iNOS was not significantly affected by TNF-α or any of the 
medications.  The addition of methyldopa, labetalol, hydralazine or clonidine did not 
alter the iNOS mRNA expression either in the presence or absence of TNF-α. This 
was the case regardless of whether endothelial cells were pre-incubated with TNF-α 
or it was added concurrently. The addition of sFlt-1 to the TNF-α pre-incubated cells 
did not alter mRNA expression of iNOS (data not shown). 
 
Discussion 
In this study, we found that antihypertensive medications commonly used for blood 
pressure control in pregnancies; methyldopa, hydralazine, clonidine and labetalol, 
counteracted the inhibitory effect of TNF-α on eNOS mRNA expression in vitro. In 
the absence of the inflammatory molecule TNF-α, these medications had no effect 
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prevented both the inhibitory effect of TNF-α and the attenuation of these 
medications on eNOS expression.  
 
In this study, prior activation of endothelial cells by TNF-α before trophoblast 
interaction is designed to mimic a very early stage of pregnancy before 
preeclampsia is clinically apparent. Whereas concurrent exposure to TNF-α during 
trophoblast integration into endothelial networks, mimics later stages of placental 
development. We found that the inhibitory effect of TNF-α on eNOS expression 
occurs independent of whether there is prior endothelial exposure to TNF-α, or 
concurrent exposure during trophoblast co-culture. Correspondingly the attenuation 
of eNOS expression by the hypertensives in the presence of TNF-α occurs 
regardless of the timing of exposure, suggesting that the hypertensives are 
modulating a factor downstream on the TNF-α pathway which in turn affects the 
eNOS response. These results are consistent with our  previous study that showed  
that the selected drugs rescued the inhibition of integration of trophoblast cells into 
endothelial networks regardless of whether there was prior or concurrent exposure 
to TNF-α, but that they had no effect on integration in the absence of TNF-α [18].  
 
Antihypertensive medications work by different mechanisms to control blood 
pressure. Methyldopa and its alternative clonidine are α2-adrenoceptor agonists that 
act on the central nervous system to control blood pressure [24]. Clonidine has also 
been reported to stimulate peripheral α2 receptors and induce vasodilatation 
through the activation of α2 receptors in endothelial cells. This effect can be blocked 










This article is protected by copyright. All rights reserved. 
this process [25]. The “rescue” effect of clonidine and methyldopa on eNOS mRNA 
expression in the presence of TNF-α shown in our in vitro model also suggests the 
involvement of endothelial α2 receptors and the NO pathway in the action of 
methyldopa and clonidine. Hydralazine relaxes arterial smooth muscle cells by 
inhibiting intracellular free calcium and consequently reducing peripheral resistance 
[26]. Our study has found that, in the presence of TNF-α, hydralazine increased 
eNOS mRNA expression in the co-cultured cells. This is in contrast to other studies 
where hydralazine was found to have no effect on eNOS production [27] [28] [22]. 
Non-selective α and β-blocker labetalol, reduces blood pressure by decreasing total 
peripheral resistance [29]. Whether this effects eNOS activity has not been 
reported. But other similar anti-hypertensive α and β-blockers such as nebivolol and 
carvidelol have been shown to have nitric oxide-potentiating vasodilatory effect [30] 
[31]. Our study suggests that labetalol does not directly affect eNOS mRNA 
expression alone, but rather that labetalol, hydralazine, methyldopa and clonidine, 
modulate the eNOS response in the presence of TNF-α. 
 
TNF-α is a proinflammatory mediator that plays a key role in cellular response to 
inflammation and injury. Elevated levels are associated with the vascular 
dysfunction of preeclampsia [15, 32] and hypertension [33]. TNF-α is required for 
trophoblast invasion in pregnancy [34], however in the exaggerated systemic 
inflammatory response of preeclampsia [35], excessive TNF-α can inhibit 
trophoblast migration and integration [16] [36] and induce endothelial cell injury [37] 
[38]. TNF-α plays a pivotal role in both the NO and the reactive oxygen species 
(ROS) pathways.  It has been shown to regulate eNOS by a pathway that involves 
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ROS by increasing NADPH oxidase leading to increased levels of the superoxide 
radical [33].Superoxide can react with NO to form the damaging peroxynitrate 
(ONOO-) which in turn, by oxidising the essential eNOS cofactor tetrahydrobiopterin 
(BH4), can lead to uncoupling of eNOS activity [9]. Additionally, superoxide can be 
converted by superoxide dismutase (SOD) to peroxide (H2O2), a molecule that has 
been reported to increase eNOS mRNA transcription and stability [40]. TNF-α may 
therefore have dual and conflicting effects on eNOS mRNA depending on the level 
of oxidative stress in the cells and the activity of the other participants in the 
complex NO and ROS pathways. The differential effect of the various anti-
hypertensive medications on eNOS expression, both in the absence and presence 
of TNF-α and in comparison to each other, may thus be a consequence of their 
individual mechanisms of action and how this action may intersect with the 
conflicting pathways of TNF-α regulation of eNOS mRNA. Labetalol, for example, 
has been shown to inhibit superoxide production [41] and thus may modulate the 
effect of TNF-α induced NADPH oxidase activity. 
 
In this study, an assessment of the effect of the hypertensive medications on NOS 
expression was carried out under conditions where both TNF-α and sFlt-1 were 
present, simulating untreated established preeclampsia. Elevated serum levels of 
both these molecules are found in preeclampsia [42] [43].  It is well documented 
that excessive placental sFlt-1 plays a significant role in the pathogenesis of 
preeclampsia [23, 42]. Experimentally, placental sFlt-1 causes a preeclampsia-like 
syndrome by antagonizing VEGF signalling, leading to endothelial dysfunction [23]. 
Recently, it has been reported that reducing sFlt-1 from the plasma of preeclamptic 
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VEGF has been shown to induce activation of eNOS by cell surface receptor 
signalling mediated phosphorylation of eNOS [45]. By acting as a decoy receptor 
sFlt-1 may inhibit this activation. A recent human study has demonstrated that 
methyldopa decreases placental and serum sFlt-1 in preeclamptic women [46]. Our 
previous in vitro data have shown that some antihypertensive medications can 
decrease sFlt-1 in the conditioned medium [18]. In the study reported here we show 
that upon endothelial cells preexposure to both sFlt-1 and TNF-α, the inhibition of 
eNOS expression observed with TNF-α alone was negated and that of the selected 
antihypertensive medicines only methyldopa slightly attenuated eNOS mRNA 
expression.  . 
 
The calcium independent inducible NOS (iNOS) can produce a large amount of NO 
(>1uM) during inflammation, exerting detrimental effects on tissue [47]. Sera 
derived from preeclamptic patients has been reported to increase mRNA expression 
of inducible NOS (iNOS) in endothelial cells [48]. In our study, the inflammatory 
molecule TNF-α did not change iNOS expression in the endothelial cell/trophoblast 
co-cultured cells, indicating that iNOS is not involved in this in vitro model. While 
clonidine has been reported to induce iNOS expression in macrophage cells [49] 
none of the selected medications had any effect on iNOS expression in this study.  
 
In summary, our data suggest that, in the presence of the inflammatory molecule 
TNF-α, some antihypertensive medications used to control blood pressure in 
pregnancy may have a common pathway to vascular relaxation via influencing nitric 
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these medications in the treatment of hypertension in pregnancy by interfering with 
the NOS pathway.  
 
Methods 
Cell culture  
Human uterine microvascular endothelial cells (UtMVEC) (PromoCell, Heidelberg, 
Germany) were cultured in EGM-2-MV medium (Lonza, Basel, Switzerland) until 
about 80% confluent. Cells from passage 4-8 were used in this study. Primary 
extravillous trophoblast HTR-8/SVneo cells (kindly provided by Dr. C.H. Graham 
from Queen’s University, Kingston, ON, Canada) were cultured with RPMI 1640 
with 5% bovine calf serum (Invitrogen, Carlsbad, CA, USA) until confluence. All 
cells were cultured under standard condition at 37oC with 5% CO2.  
 
Co-culture of endothelial cells and HTR-8/SVneo cells on Matrigel with 
methyldopa, labetalol, hydralazine, or clonidine, with/without TNF-α.  
Tissue culture plates (24-wells) were coated with undiluted Matrigel (300µl/well, In 
Vitro Technologies, Noble Park, VIC, Australia) and polymerized for 30 minutes at 
37oC. UtMVECs (100,000 cells/well) were seeded into each well and endothelial cell 
tubular networks formed within 4 hours of further incubation at 37°C. HTR-8/SVneo 
cells (100,000 cells/well) were then added to each well with or without a low dose of 
TNF-α (0.5 ng/mL) together with methyldopa (5 µg/ml), labetalol (0.5 µg/ml), 
hydralazine (10 µg/ml) or clonidine (1.0 µg/ml) and co-cultured with the endothelial 
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concentrations during therapeutic use in humans[18]. The control co-cultured cells 
had neither TNF-α nor medications added.  After 24 hours of culture, the cells were 
retrieved from the cellular networks in Matrigel with Cell Recovery Solution (CRS) 
(In Vitro Technologies, Noble Park, VIC, Australia) for RNA extraction according to 
manufacturer’s instructions. Each treatment was performed 6 times (n = 6). 
 
Pre-incubation of UtMVECs with TNF-α and sFlt-1 
For some experiments the UtMVECs were pre-incubated with low dose of TNF-α 
(0.5 ng/ml) alone (pre-TNF-α treated group) or TNF-α in combination with sFlt-1 
(100 ng/ml) (pre-TNF-α+sFlt-1 treated group) in the culture flask for 24 hours. 
These cells were then trypsinized, washed 3 times with PBS and were ready for co-
culture. No further TNF-α was added during co-culture. 
 
Both UtMVECs and HTR-8/SVneo cells were above 85% viable in all experiments, 
as monitored by trypan blue staining. None of the medications affected the cellular 
network formation when applied to endothelial cells alone, nor did they affect 
trophoblast/endothelial cell integration in the absence of TNF-α [18] 
 
RNA Extraction and Quantitative-PCR (Q-PCR) Analysis 
Total RNA was extracted from the co-cultured cell pellets retrieved from Matrigel 
stated above using Qiagen RNA extraction kit (Qiagen, Doncaster, VIC, Australia) 
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free water (20-40 μL). The RNA concentration was quantified by spectrophotometry 
(Nanodrop Technologies, Rockland, DE, USA). Specific cDNA was reverse 
transcribed from 100 ng of total RNA using iSCRIPT (Bio-Rad, Regents Park, NSW, 
Australia), according to the manufacturer’s protocol. An aliquot of each cDNA 
sample (1μl) was amplified by real-time PCR in reaction mixtures containing primers 
and iQ SYBR Green Supermix. Amplification was performed in a Bio-Rad iQ5 
thermocycler (Bio-Rad) using the following protocol: 95 °C for 30 secs, annealing 
temperature (Ta) of specific primer sets for 30 secs and 72 °C for 30 secs. Real 
time data was measured by quantifying fluorescence during the elongation phase at 
72 °C in each cycle. After the completion of amplification, the threshold cycle (CT) 
was calculated using iCycler iQ Real Time PCR detection system software version 
3.0A (BioRad, Gladesville, NSW, Australia). Primer pairs sequences of the 
assessed genes are eNOS (forward, 5’- GGACTTCATCAACCAGTAC-3’, reverse, 
5’-GATGTAGGTGAACATTTCC-3’), iNOS (forward, 5’- 
CAAGCAGCAGAATGAGTC-3’, reverse, 5’- GCCTTATGGTGAAGTGTG -3’) [17]. 
Relative changes in mRNA gene expression were determined by the ΔΔCT method 
using β-actin (forward, 5’-ATGTGGCCGAGGACTTTGATT-3’, reverse, 5’-
AGTGGGGTGGCTTTTAGGATG-3’) as the housekeeping gene [50, 51]. 
Expression levels were reported as a percentage of the non-treated control group.  
 
Statistical Analysis 
Data are expressed as mean ± sem % of control. Statistical analysis was performed 
using Graphpad Prism version 5.0d for Mac OSX (GraphPad Software, San Diego 
California USA). Differences between groups were assessed by non-parametric 
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Sharpened Bonferroni method was used to adjust the individual α level when 
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Table1. Comparison of antihypertensive medications on the relative expression of eNOS 
mRNA in endothelial/trophoblast co-culture system 
 
 
medication TNF-α pre-incubated with 
endothelial cells 
TNF-α added concurrently 
with medications 
methyldopa 87 ± 15 % 109 ± 15 % 
labetalol 170 ± 26 % * 144 ± 38 % 
hydralazine    192 ± 43 %  **     286 ± 74 % ** 
clonidine 146 ± 15 % 210 ± 48 % 
 
Data is expressed as mean ± sem and levels are relative to control cells co-cultured with no 
additions and normalised to ß-actin expression levels. 
* Indicated a significant difference compared with methyldopa.  
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